Jane Street Group LLC Trims Stock Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Jane Street Group LLC lessened its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 27.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,721 shares of the company’s stock after selling 57,048 shares during the quarter. Jane Street Group LLC owned 0.25% of Health Catalyst worth $1,235,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. First Light Asset Management LLC boosted its position in shares of Health Catalyst by 438.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares during the period. Millennium Management LLC lifted its stake in Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after purchasing an additional 1,184,131 shares in the last quarter. Nepsis Inc. lifted its stake in Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after purchasing an additional 851,448 shares in the last quarter. Fred Alger Management LLC purchased a new position in shares of Health Catalyst during the third quarter worth $6,858,000. Finally, Portolan Capital Management LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at $5,402,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on HCAT shares. Stephens increased their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. increased their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Friday, October 4th. Royal Bank of Canada upped their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Finally, Citigroup raised their price target on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.79.

Health Catalyst Price Performance

Shares of HCAT opened at $7.08 on Friday. The firm has a market capitalization of $430.80 million, a price-to-earnings ratio of -5.24 and a beta of 1.31. The firm’s fifty day simple moving average is $7.96 and its 200-day simple moving average is $7.47. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.22) earnings per share. Equities analysts forecast that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Insider Transactions at Health Catalyst

In related news, Director Duncan Gallagher sold 4,500 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $6.98, for a total value of $31,410.00. Following the completion of the sale, the director now directly owns 74,438 shares of the company’s stock, valued at $519,577.24. The trade was a 5.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the transaction, the chief operating officer now directly owns 134,899 shares in the company, valued at approximately $1,036,024.32. The trade was a 3.72 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,051 shares of company stock valued at $563,515. Corporate insiders own 2.50% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.